Bystander elimination of antigen loss variants in established tumors.
about
Synopsis of the 6th Walker's Cay Colloquium on Cancer Vaccines and ImmunotherapyStromal interferon-γ signaling and cross-presentation are required to eliminate antigen-loss variants of B cell lymphomas in miceThe application of the fibroblast activation protein α-targeted immunotherapy strategyType I interferon is selectively required by dendritic cells for immune rejection of tumorsA vaccine that co-targets tumor cells and cancer associated fibroblasts results in enhanced antitumor activity by inducing antigen spreadingImmunosuppressive strategies that are mediated by tumor cellsEnhanced cancer radiotherapy through immunosuppressive stromal cell destruction in tumorsRelapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinityTwo-photon imaging of intratumoral CD8+ T cell cytotoxic activity during adoptive T cell therapy in mice.Longitudinal confocal microscopy imaging of solid tumor destruction following adoptive T cell transfer.Dendritic cell cross-priming is essential for immune responses to Listeria monocytogenes.CCL21 and IFNγ recruit and activate tumor specific T cells in 3D scaffold model of breast cancer.Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hostsAdoptive transfer of tumor-specific Tc17 effector T cells controls the growth of B16 melanoma in miceAdoptively transferred immune T cells eradicate established tumors despite cancer-induced immune suppression.Shaping the repertoire of tumor-infiltrating effector and regulatory T cells.Oncogene-targeting T cells reject large tumors while oncogene inactivation selects escape variants in mouse models of cancer.The manipulation of immunity. Conference on from allergy to cancer: new perspectives for therapeutic vaccinationBystander killing of cancer requires the cooperation of CD4(+) and CD8(+) T cells during the effector phase.Vaccination with embryonic stem cells protects against lung cancer: is a broad-spectrum prophylactic vaccine against cancer possible?Tumor expression of CD200 inhibits IL-10 production by tumor-associated myeloid cells and prevents tumor immune evasion of CTL therapy.A novel HLA-B18 restricted CD8+ T cell epitope is efficiently cross-presented by dendritic cells from soluble tumor antigen.Design of T-cell receptor libraries with diverse binding properties to examine adoptive T-cell responses.Trial Watch: Peptide-based anticancer vaccines.In vivo antigen delivery by a Salmonella typhimurium type III secretion system for therapeutic cancer vaccines.Endogenous T cell responses to antigens expressed in lung adenocarcinomas delay malignant tumor progression.Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens.Targeting c-MYC with T-cellsCD134 plus CD137 dual costimulation induces Eomesodermin in CD4 T cells to program cytotoxic Th1 differentiation.IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors.IL-10 contributes to the suppressive function of tumour-associated myeloid cells and enhances myeloid cell accumulation in tumours.Consensus nomenclature for CD8(+) T cell phenotypes in cancerTrial watch: Naked and vectored DNA-based anticancer vaccinesAdoptive transfer of tumor-primed, in vitro-activated, CD4+ T effector cells (TEs) combined with CD8+ TEs provides intratumoral TE proliferation and synergistic antitumor response.CD4 cells can be more efficient at tumor rejection than CD8 cellsExploiting natural anti-tumor immunity for metastatic renal cell carcinoma.Proteasome inhibition blocks NF-κB and ERK1/2 pathways, restores antigen expression, and sensitizes resistant human melanoma to TCR-engineered CTLsRandom migration precedes stable target cell interactions of tumor-infiltrating T cells.Induced sensitization of tumor stroma leads to eradication of established cancer by T cells.Induction of tumoricidal function in CD4+ T cells is associated with concomitant memory and terminally differentiated phenotype
P2860
Q24798754-EA4FD469-F8C0-4EA4-A486-5693353E053BQ27305136-8C12085F-64E3-4E84-8222-C68F146B218BQ28073437-AD4E5DDD-03D9-4C9B-88F8-7382A9D981DDQ28248500-9DBF37E9-F3A9-4198-8FA0-15704CCEF2F0Q28537598-FE7FBDA1-E918-4BE9-B584-244C4FD0D093Q29636247-2C1F37D1-BDC7-4F9B-9E12-027BAFAB76A2Q30408302-7D53A0D6-3595-4DBA-BAA4-C0E3696680B5Q30413827-EB0A80C4-789D-4B89-8240-9C590CC04817Q30481516-F82C0C09-135B-41CC-A13C-DD1E7E9461EEQ30565493-6B33DA95-ADD0-44B6-B3B0-7607FE6339D6Q33508800-F816352B-C286-46BD-BE2B-2044EB63D954Q33726546-EF3C2940-68EE-4F3F-B9A1-30A7CCBBAF49Q33730171-42045BFB-6888-43AB-B242-82980AE9C296Q33776452-6D103B2E-D316-44C5-8D5D-5F688FD00CAEQ33854515-6081461E-E304-40B8-BAF5-8B08A6FAE3F9Q34003592-724F2DEF-BEAE-4838-8957-FE9D512BAB98Q34102216-DE4ECFE3-F0D2-4B1C-A719-D14393A2904AQ34166187-82771789-79FF-400F-B8B5-F2B96E4F4F5FQ34243372-467F4139-0F6D-49B7-956F-0E5F8B4E3267Q34364763-A58A1D12-ABAE-4B56-83F1-EBA0A74CA17EQ34412294-26A657F8-C4D4-4660-86B2-E2DAD5E09C9AQ34412732-D85C5560-C817-4342-AB85-ACF291FD6887Q34439729-03CF279B-22AF-4802-B737-18ACF501810FQ34483345-3B1A617B-BF13-422A-9E5F-94F72A74AD8AQ34691545-1DD8F0A4-0C4E-46B0-B7D2-BA4FDF946AE6Q34755544-5A19FAA8-FD95-40FF-BC2C-F68693767BA2Q34788858-36EEA37D-4BFF-4683-8E7A-558C23678810Q35018846-7296391C-6A0A-4948-B25C-DBBA88267CC1Q35228053-7ABD4129-8AEC-401D-9A69-0AAACD0ECDEEQ35578622-8A8F1095-B87D-46B1-B1D7-E979FCA7BAB0Q35757368-4067BA6C-E684-4ABE-998A-074159DD71A4Q35798822-78B635E6-D8AE-4464-8DE3-FE3576133801Q35798986-992809AD-7481-4DD3-9950-E65861B57A86Q35828752-49FA99F1-24EA-43A8-B48E-A7D45D0D4DD6Q35839925-9E17CB15-45B7-4B45-A04A-8B85A0EB3AD0Q35887319-CC6D7EE8-AF6A-4129-9206-4265D27D737BQ36028423-BF551621-7F46-451D-9C77-24F22A4F5DC9Q36228164-46C66437-B7CB-4512-8943-1F8B35D5C3C8Q36228950-04C6FC92-F3BC-4F09-BF23-40DC48C57FF8Q36340873-6F21DCD4-220F-4375-820D-245A890C9C8D
P2860
Bystander elimination of antigen loss variants in established tumors.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Bystander elimination of antigen loss variants in established tumors.
@en
Bystander elimination of antigen loss variants in established tumors.
@nl
type
label
Bystander elimination of antigen loss variants in established tumors.
@en
Bystander elimination of antigen loss variants in established tumors.
@nl
prefLabel
Bystander elimination of antigen loss variants in established tumors.
@en
Bystander elimination of antigen loss variants in established tumors.
@nl
P2093
P356
P1433
P1476
Bystander elimination of antigen loss variants in established tumors.
@en
P2093
Donald A Rowley
Hans Schreiber
Michael T Spiotto
P2888
P304
P356
10.1038/NM999
P407
P577
2004-02-22T00:00:00Z